GlobeNewswire by notified

Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC

Share

STOCKHOLM, SWEDEN – May 8, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has randomized its first two patients to the second part of the ongoing clinical phase 1b/2 study of golexanolone in patients with Primary Biliary Cholangitis, PBC. Top-line results are expected in first half of 2025.

Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in a randomized, double-blind, placebo-controlled, clinical phase 1b/2 study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms. Following recent authorization from Umecrine Cognitions internal safety review committee (iSRC), to proceed to the second part of the study, the aim is now to evaluate the preliminary efficacy of golexanolone, as well as continue the documentation of the drug candidate's safety and tolerability profile.

The second part of the study is expected to include 84 patients at 30 clinical research centers across Europe. As part of the data evaluation, an interim analysis will be performed when three-quarters of the patients are included. Based on the current timeline, the company expects to communicate top-line results in H1, 2025.

Karolinska Development's ownership in Umecrine Cognition amounts to 73 percent.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.


Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Weekly share repurchase program transaction details29.5.2024 18:33:44 CEST | Press release

May 29, 2024 SBM Offshore reports the transaction details related to its EUR65 million (c. US$70 million) share repurchase program for the period May 23, 2024 through May 29, 2024. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024 and effective from March 1, 2024. The objective of the program is to reduce share capital. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period March 1, 2024 through May 29, 2024 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase ProgramOverall progress Share Repurchase Program:Total Repurchase AmountEUR 65,000,000Cumulative Repurchase AmountEUR 21,944,332Cumulative Quantity Repurchased1,553,031Cumulative Ave

Progress on cosmetics plant project: completion of the basic engineering phase and success of the related test campaign29.5.2024 17:45:00 CEST | Press release

PRESS RELEASE Progress on cosmetics plant project: completion of the basic engineering phase and success of the related test campaign Evry, 29 May 2024 – 05:45 p.m.: Global Bioenergies has successfully completed the basic engineering phase of its plant project dedicated to the cosmetics markets whose commissioning is scheduled for mid-2027. The engineering work carried out as part of the basic engineering has precisely defined the each of the units that will enable the fully integrated production of cosmetic-grade isobutene derivatives. It also confirms the project schedule and the nominal CAPEX of 65 million euros (i.e. a maximum CAPEX of 80 million euros taking into account contingencies). Roland Desvignes, Industrial Director of Global Bioenergies, explains: “Two engineering firms have been mandated, the first to handle the biological side, and the second the part dedicated to green chemistry. Their respective expertise gives us a very good vision of the plant's blueprints. We are n

Vaisala Corporation: Share Repurchase 29.5.202429.5.2024 17:30:00 CEST | Press release

VAISALA CORPORATIONSTOCK EXCHANGE RELEASE 29.5.2024Vaisala Corporation: Share Repurchase 29.5.2024In the Helsinki Stock ExchangeTrade date 29.5.2024Bourse trade BuyShare VAIASAmount 500SharesAverage price/ share 39,9700EURTotal cost 19 985,00EURVaisala Corporation now holds a total of 138 828 sharesincluding the shares repurchased on 29.5.2024On behalf of Vaisala CorporationNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information Paula Liimattatel +358 9 8949 2020, ir@vaisala.comwww.vaisala.com Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of over 2,300 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.vaisala.com

Thierry Amarger co-opted as independent Director by Vantiva29.5.2024 17:30:00 CEST | Press release

Press Release Thierry Amarger co-opted as independent Director by Vantiva Paris, France – May 29, 2024 – Vantiva (Euronext Paris: VANTI), announced that on the recommendation of the Governance and Social Responsibility Committee, Vantiva's Board of Directors, convened on May 28, 2024, to co-opt Thierry Amarger as an independent Director of Vantiva. He replaces Dominique D'Hinnin, who resigned on April 5, 2024. This co-option took effect immediately. Thierry Amarger's co-option will be submitted to shareholders for ratification at the Annual General Meeting to be held on June 19, 2024. His term of office will expire at the close of the Annual General Meeting for fiscal year 2024. Brian Shearer, Chairman of the Board of Directors, said: “I welcome Thierry Amarger to our Board of Directors. He is a proven leader within multiple areas of the global telecommunications ecosystem, and his skillset will be immediately beneficial to all Vantiva stakeholders.” Mr. Amarger, a French national, is

Zealand Pharma to participate in upcoming healthcare investor conferences in June 202429.5.2024 17:10:00 CEST | Press release

Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Adam Steensberg, President and CEO, will participate in fireside chats at the following healthcare investor conferences in June: Jefferies Global Healthcare Conference, June 4-6 in New York City Wednesday, June 5 at 10:00 a.m. ET (4:00 p.m. CET) A webcast of the fireside chat will be available at https://wsw.com/webcast/jeff302/register.aspx?conf=jeff302&page=zeal&url=https://wsw.com/webcast/jeff302/zeal/1839808 and accessible through the Events page in the Investor section of Zealand Pharma’s website at https://www.zealandpharma.com/events/ where a replay will also be archived after the fireside chat. Goldman Sachs 45th Annual Global Healthcare Conference, Jun

HiddenA line styled icon from Orion Icon Library.Eye